Spots Global Cancer Trial Database for RC48-ADC in Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: RC48-ADC in Breast Cancer
Official Title: Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real World Study
Study ID: NCT05851677
Conditions
Interventions
Study Description
Brief Summary: To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, , China
Contact Details
Name: Wenjin Yin, M.D.
Affiliation: Renji Hospital,School of Medicine, Shanghai Jiaotong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
